Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 21;26(23):5231-5244.
doi: 10.1002/chem.201905599. Epub 2020 Apr 6.

Solution Conformations Explain the Chameleonic Behaviour of Macrocyclic Drugs

Affiliations

Solution Conformations Explain the Chameleonic Behaviour of Macrocyclic Drugs

Emma Danelius et al. Chemistry. .

Abstract

It has been hypothesised that drugs in the chemical space "beyond the rule of 5" (bRo5) must behave as molecular chameleons to combine otherwise conflicting properties, including aqueous solubility, cell permeability and target binding. Evidence for this has, however, been limited to the cyclic peptide cyclosporine A. Herein, we show that the non-peptidic and macrocyclic drugs roxithromycin, telithromycin and spiramycin behave as molecular chameleons, with rifampicin showing a less pronounced behaviour. In particular roxithromycin, telithromycin and spiramycin display a marked, yet limited flexibility and populate significantly less polar and more compact conformational ensembles in an apolar than in a polar environment. In addition to balancing of membrane permeability and aqueous solubility, this flexibility also allows binding to targets that vary in structure between species. The drugs' passive cell permeability correlates to their 3D polar surface area and corroborate two theoretical models for permeability, developed for cyclic peptides. We conclude that molecular chameleonicity should be incorporated in the design of orally administered drugs in the bRo5 space.

Keywords: NMR spectroscopy; antibiotics; conformation analysis; drug design; macrocycles.

PubMed Disclaimer

References

    1. C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Adv. Drug Delivery Rev. 1997, 23, 3-25.
    1. A. L. Hopkins, C. R. Groom, Nat. Rev. Drug Discovery 2002, 1, 727-730.
    1. S. Surade, T. L. Blundell, Chem. Biol. 2012, 19, 42-50.
    1. B. C. Doak, B. Over, F. Giordanetto, J. Kihlberg, Chem. Biol. 2014, 21, 1115-1142.
    1. E. M. Driggers, S. P. Hale, J. Lee, N. F. Terrett, Nat. Rev. Drug Discovery 2008, 7, 608-624.

Substances

LinkOut - more resources